Inside the Medicare GLP-1 Coverage Demonstration Discussions
Proposals to expand Medicare coverage of GLP-1 drugs for obesity have circulated for several budget cycles. Here's what's actually been proposed versus enacted.
By the GLP Semaglutide editorial team · Last updated June 10, 2026
Medicare Part D has historically excluded coverage of drugs used solely for weight loss under a statutory exclusion dating to the program's original design. Various legislative and administrative proposals have sought to change this specifically for anti-obesity medications.
Proposed vs. enacted
A proposal being discussed, introduced as a bill, or covered by a CMS demonstration announcement is not the same as an enacted, funded policy change. Some proposed changes have advanced through partial administrative action (such as coverage tied to a specific on-label indication) without a full statutory exclusion repeal.
Where to verify current status
CMS publishes official coverage determinations and demonstration program details directly. Given how often this topic is discussed in the news without a policy change actually taking effect, checking CMS's own materials is the only reliable way to know current status.
Primary sources